KIDO TSUNEO has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2012. It filed its patents most often in Australia, China and New Zealand. Its main competitors in its focus markets biotechnology and pharmaceuticals are BALTIC TECHNOLOGY DEV LTD, ISIS PHARMACEUTICAL INC and GENEPOD THERAPEUTICS AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 2 | |
#2 | China | 2 | |
#3 | New Zealand | 2 | |
#4 | Taiwan | 2 | |
#5 | Argentina | 1 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | Chile | 1 | |
#9 | EAPO (Eurasian Patent Organization) | 1 | |
#10 | Republic of Korea | 1 | |
#11 | Mexico | 1 | |
#12 | Singapore | 1 | |
#13 | United States | 1 | |
#14 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Kido Tsuneo | 18 |
Publication | Filing date | Title |
---|---|---|
TW201319253A | Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro | |
CA2821065A1 | Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro |